Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics".
Sci Transl Med
; 13(622): eabf4530, 2021 12.
Article
in En
| MEDLINE
| ID: mdl-34851696
ABSTRACT
Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
Type of study:
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Sci Transl Med
Journal subject:
CIENCIA
/
MEDICINA
Year:
2021
Document type:
Article
Affiliation country: